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ments (time-tradeoff amounts) for inﬂuenza-related events were
based on primary data from a telephone survey (n = 112). Incre-
mental cost-effectiveness ratios in dollars per quality-adjusted
life year (QALY) were calculated. RESULTS: For an unvacci-
nated population, the base case cost per QALY for empirical
treatment with amantadine was less than $1000 for all sub-
groups and for empirical treatment with oseltamivir ranged from
less than $1000 to $8000 depending on age and risk status.
Results were sensitive to inﬂuenza illness rate, proportion of
inﬂuenza-like illness that is conﬁrmed inﬂuenza, and inﬂuenza
vaccination status. Testing and treatment options were more
costly and less effective than empirical treatment options. Prob-
abilistic sensitivity analysis suggests that empirical treatment
with amantadine has similar cost-effectiveness ratios under many
scenarios while the cost-effectiveness ratios of empirical treat-
ment with oseltamivir show wider variability. CONCLUSIONS:
Empirical treatment with amantadine during peak inﬂuenza
season is notably more cost-effective than empirical treatment
with oseltamivir. Both reductions in test prices and improvement
in accuracy of rapid inﬂuenza tests will be needed to make testing
and treatment strategies attractive alternatives.
ARTHRITIS
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ASSESSING THE COST-EFFECTIVENESS OF COX-2 SPECIFIC
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OBJECTIVE: This study was designed to assess the cost-
effectiveness of cyclooxygenase-2 speciﬁc (COX-2) inhibitors
(rofecoxib and celecoxib) over non-selective non-steroidal anti-
inﬂammatory drugs (NSAIDs) in high-risk arthritis patients from
the perspective of the Veterans Health Administration (VA).
METHODS: This literature-based economic analysis compared
rofecoxib and celecoxib to NSAIDS in two arthritis patient pop-
ulations considered at higher risk of developing clinically signif-
icant upper gastrointestinal events (CSUGIEs): 1) patients of any
age with previous medical history of perforation/ulcer/bleed
(PUB), and 2) patients 65 years and older (regardless of history
of PUB). Two outcomes measures were reported 1) incremental
cost per CSUGIE averted over 1 year, and 2) incremental cost
per quality-adjusted life-year (QALY) gained, considering both
the mortality and morbidity associated with gastrointestinal
(including CSUGIEs) and cardiovascular-related adverse events.
When possible, costs were modeled to reﬂect the VA perspective.
Sensitivity analyses were conducted to test the robustness of the
analysis. RESULTS: Compared to NSAIDS, rofecoxib and cele-
coxib increased costs but reduced the incidence of CSUGIE. Cost
per CSUGIE avoided were $7,476 and $16,379 (in patients with
a PUB history) and $14,294 and $18,376 (in patients aged > 65
years) for celecoxib and rofecoxib, respectively. In both popula-
tions, celecoxib was associated with a cost per QALY less than
$50,000. In contrast, rofecoxib was found to cost more and
result in a net QALYs loss, due in particular to the increase in
the risk of cardiovascular complications, and was therefore con-
sidered cost-ineffective. Results were most dependent on assump-
tions about the incidence of cardiovascular events and CSUGIE
and the COX-2 inhibitors acquisition price. CONCLUSIONS:
This analysis suggests that the COX-2 inhibitors may be cost-
effective from the perspective of the VA. However, cost-
effectiveness appears to depend less on the speciﬁc characteris-
tics of the high-risk target population considered but more on
the agent evaluated.
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OBJECTIVE: The present study compared the cost-effectiveness
of four biologics—adalimumab, anakinra, etanercept, and inﬂix-
imab—used in the treatment of rheumatoid arthritis (RA).
METHODS: A decision analytic model was constructed to esti-
mate the costs and effectiveness of these biologics used alone or
in combination with methotrexate (MTX) during one year, from
the perspective of a managed-care organization. Direct costs 
consisted of drugs and health care resources. Effectiveness was
measured by Quality-Adjusted Life Years (QALYs) based on
preference weights and health states in which patients achieved
one of four levels of response according to the American College
of Rheumatology (ACR) response criteria (No ACR 20, ACR20,
ACR50, ACR70) and had one of the four levels of adverse effects
(no, mild, moderate, severe) due to their treatments. Drug costs
were US average wholesale price. Costs for health care resources
were those published by the Committee of Medicare and Med-
icaid Services and in the MEDSTAT DRG Guide. Preference
weights were obtained from a survey on patients with RA in
which visual analogue scale technique was used. Probabilities of
health states were derived from published clinical trial reports.
One-way sensitivity analyses were conducted on all variables to
test for robustness of the model. RESULTS: Among monother-
apies, the incremental cost-effectiveness ratio (ICER) of etaner-
cept compared to anakinra (the lowest cost option) was $13,387
per additional QALY, while etanercept dominated adalimumab.
Among combination therapies, the ICER of etanercept + MTX
compared to anakinra + MTX was $7925 per additional QALY.
Etanercept combination therapy dominated adalimumab and
inﬂiximab combination therapies. However, the costs of etaner-
cept + MTX and adalimumab + MTX were almost equal. Results
were sensitive to changes in treatment costs and probabilities of
health states in directions as predicted. CONCLUSIONS: For
monotherapy and combination therapy regimens, anakinra was
the least expensive option while etanercept dominated other
treatments.
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OBJECTIVE: This study reassessed the psychometric character-
istics of the original 33-item CSHQ-RA instrument using a rep-
resentative population of RA patients from 55 sites across the
US. METHODS: Three hundred seven of 309 screened patients
from a 24-week multicenter, open-label, single arm study of RA
patients receiving anakinra completed the 33-item CSHQ-RA,
the Medical Outcomes Study Short Form-36 (MOS SF-36) 
and the Stanford Health Assessment Questionnaire (HAQ) 
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Disability Index. Data at screening and baseline were used to
examine the convergent validity, discriminant validity, internal
consistency, and test-retest reliability. Convergent validity was
tested, using Pearson’s correlations, by comparing total and sub-
scale scores on the CSHQ-RA to those from the Mental and
Physical Component Summary (MCS and PCS) of the MOS SF-
36 and HAQ. ANOVA and Kruskal-Wallis tests were used to
assess the discriminant validity of the CSHQ-RA. Internal 
consistency was measured by Cronbach’s alpha coefﬁcient.
Test–retest reliability was assessed using intraclass correlation
coefﬁcients (ICCs). RESULTS: Response rate at baseline was
95% (291). Eighty-one percent of respondents were female;
mean age was 52 years (± 12); mean duration with RA was 10.8
years (± 10.4). At baseline, mean scores on instruments were
HAQ 1.5 (± 0.7), MCS 37.9 (± 10.9), and PCS 31.2 (± 8.3).
Pearson’s correlations between the CSHQ-RA and the MOS SF-
36 and HAQ scores ranged from -0.33 to -0.73 (P < 0.0001)
and 0.39 to 0.76 (P < 0.0001), respectively. The difference in
scores on the CSHQ-RA of patients with different levels of phys-
ical disability as measured by the HAQ was statistically signiﬁ-
cant (P < 0.0001). Cronbach’s alpha coefﬁcients were ≥0.9
indicating good internal consistency. Test-retest reliability was
demonstrated in the instrument’s subscales with ICCs ranging
from 0.82 to 0.94. CONCLUSIONS: These results support the
validity and reliability of the original CSHQ-RA when tested in
a representative patient population. Research to assess respon-
siveness and clinically signiﬁcant change of the CSHQ-RA is
underway.
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THE DEVELOPMENT OF PROPENSITY SCORES FROM
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OBJECTIVES: The Nova Scotia Osteoarthritis (OA) Academic
Detailing Service is voluntary and as such questions of selection
bias when comparing the physicians’ prescribing behaviour that
volunteered with those that did not are justiﬁed. The objective
is to abate this bias, using propensity score methodology to
create balanced experimental groups for the analysis of pre-
scribing behaviour. METHODS: A total of 989 of the 1403
general practicioners in Nova Scotia met the inclusion criteria
for the study (312 received the OA service, 677 did not). The
propensity score for each physician was calculated using a logis-
tic regression analysis; with participation in the OA service as
the dependent variable and 10 independent variables that
described the physician’s personal and practice characteristics.
RESULTS: The 10 independent variables were tested for signif-
icant differences (alpha = 0.05, t-test for continuous and chi-sq
for catagorical variables) before and after the propensity analy-
sis was conducted. Nine of the 10 variables showed signiﬁcant
difference between the experimental groups in the pre-
propensity comparison whereas only 1 variable showed a sig-
niﬁcant difference in the post-propensity comparison. CON-
CLUSIONS: The propensity score methodology was successful
in abating selection bias by eliminating signiﬁcant differences
between variables measuring physician characteristics. It also
identiﬁed one variable (participation in a previous inﬂuenza
detailing service), which remained a signiﬁcant predictor of 
participation in the OA service after the propensity score was
completed (pre-propensity chisq = 407.48, p < 0.0001 and 
post-propensity chisq = 15.46, p < 0.0001). As such, there is a
strong argument that this variable should be included as a covari-
ate in the statistical analysis of behavioural differences between
the groups.
SESSION II
HEALTH CARE REIMBURSEMENT
HR1
DO DRUG PRICES REFLECT VALUE? DO FORMULARY
POLICIES?
Neumann PJ, Lin PJ, Rosen AB, Greenberg D, Olchanski NV,
Weinstein MC
Harvard School of Public Health, Boston, MA, USA
OBJECTIVES: Prescription drugs that provide high value should
command higher prices than lower value drugs other things
equal. We examined correlations between a drug’s price and its
economic merit, as measured in cost-utility analysis (CUAs). We
also examined whether formularies policies are consistent with
cost-utility (CU) ratios. METHODS: CUAs from 1998 through
2001 on pharmacotherapies were selected from a large registry
of analyses. All CU ratios and drug cost estimates were taken as
reported in analyses and standardized to 2002 US$. Spearman
correlation coefﬁcients were used to quantify the association
between drug prices and CU ratios. We examined the Florida
Medicaid Preferred Drug List and Harvard Pilgrim Pharmacy
Program to analyze whether insurers cover drugs with good
value. Wilcoxon rank sum test was performed to assess if pre-
ferred drugs had different ratios than non-preferred drugs.
RESULTS: Of 205 ratios, 16.1% were for short-term treatment
(<2 months), 29.8% intermediate treatment (2–18 months), and
54.2% lifetime treatment. Ten and seven-tenths percent of ratios
were cost saving and 8.3% dominated. Correlations between
ratios and prices were 0.4991 (p = 0.0069), 0.1154 (p = 0.4724)
and 0.2892 (p = 0.0041) for short, intermediate, and lifelong
drugs, respectively. CU ratios did not differ signiﬁcantly from
preferred to non-preferred drugs on both health plans. Among
cost-saving therapies, only 68.2% were covered by Florida Med-
icaid and 72.7% by Harvard Pilgrim. Among dominated drug
interventions, 88.2% were covered by Florida Medicaid and
94.12% by Harvard Pilgrim. CONCLUSIONS: CU ratios of
pharmacotherapies are positively associated with price, but the
correlation is low among intermediate and lifelong treatments.
Preferred drugs on two health plans generally do not reﬂect
better cost-effectiveness. These results may reﬂect the absence of
value-based pricing and lack of evidence-based reimbursement
policies, or the fact that CUAs are poorly conducted (e.g., they
have inappropriate comparators), or do not reﬂect decision
makers’ perceptions of value.
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OBJECTIVE: To investigate the perceptions, concerns and atti-
tudes of decision-makers regarding access to HCDs in public
hospitals. METHODS: In-depth, semi-structured interviews
were conducted with public hospital senior managers, directors
of pharmacy and senior medical doctors in a Sydney Area Health
Service. Topics for the interviews included the decision-making
process and associated problems and solutions to matters of
access to HCDs. Interviews were audiotaped, transcribed verba-
tim, thematically content analyzed and coded using NVivo soft-
ware. RESULTS: Data analysis identiﬁed a number of emerging
themes. Decision-makers perceived health care system funding
